Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of July 2021, with a specific transaction date of July 7, 2021. The report serves as a transaction notification regarding a Person Discharging Managerial Responsibilities (PDMR) rather than a periodic financial performance report.
Key Financial Metrics
The filing does not provide corporate financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to a specific insider transaction:
- Instrument: American Depositary Shares (ADSs)
- Transaction Price: $40.24 per ADS
- Transaction Volume: 1,150.686 ADSs
- Transaction Type: Acquisition within an Executive Supplemental Savings Plan
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely discloses an initial notification of an acquisition by a senior executive.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, contingencies, or discussion of unusual items. It is a regulatory disclosure of a specific securities transaction.
Key Facts for Investor Verification
- Executive Action: Dr. H Barron, Chief Scientific Officer and President, R&D, acquired notional ADSs.
- Transaction Context: The acquisition occurred within the GSK Executive Supplemental Savings Plan account, not necessarily a direct open-market purchase.
- Market Data: The transaction took place on the New York Stock Exchange (XNYS) at a price of $40.24.
- Reporting Limitation: This document does not contain quarterly or annual financial results; investors should refer to Form 20-F or press releases for performance data.